BioSpace News Archive

Global Blood Therapeutics, Inc. announced positive results from real-world and long-term studies with Oxbryta® tablets for the treatment of sickle cell disease.

Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, presented new preclinical data supporting the safety and efficacy profile of WU-CART-007 for T-cell malignancies.

Brii Biosciences Limited, a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, announced new in vitro pseudoviris neutralization data demonstrating that its amubarvimab/romlusevimab combination therapy retains activity against the new Omicron SARS-CoV-2 variant.

Sangamo Therapeutics, Inc. announced updated preliminary proof-of-concept clinical data from the Phase 1/2 PRECIZN-1 study of SAR445136, a zinc finger nuclease gene-edited cell therapy candidate in development with Sanofi for the treatment of sickle cell disease.

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that updated initial safety and efficacy findings from the Phase 1b/2 study of IMGN632 in combination with Vidaza® and Venclexta® in patients with relapsed/refractory acute myeloid leukemia were presented in an oral session at the 63rd American Society of Hematology Annual Meeting.

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company, announced updated clinical data from the pirtobrutinib global Phase 1/2 BRUIN clinical trial in patients with chronic lymphocytic leukemia, small lymphocytic lymphoma and mantle cell lymphoma.

Imago BioSciences, Inc., a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms, presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with essential thrombocythemia.

ELEVATE-RR head-to-head trial data also presented at ASH showed patients on ibrutinib experienced a 37% higher burden of adverse events of any grade while on treatment vs. patients on CALQUENCE.

Editas Medicine, Inc., a leading genome editing company, reported in vitro and in vivo preclinical data on the enhanced tumor killing capacity of two modified induced pluripotent stem cell -derived natural killer cell therapies using Editas Medicine’s proprietary AsCas12a gene editing.

Innovent Biologics, Inc and IASO Biotherapeutics jointly announced the latest data from the phase 1/2 clinical study of a fully human B-cell maturation antigen chimeric antigen receptor T-cell therapy in an oral presentation at the 63rd American Society of Hematology Annual Meeting.